共 50 条
- [1] A randomized phase 2 trial of erlotinib versus pemetrexed as second-line therapy in the treatment of patients with advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinomaCANCER, 2014, 120 (09) : 1379 - 1386Li, NingOu, WeiYang, HuaLiu, Qian-WenZhang, Song-LiangWang, Bao-XiaoWang, Si-Yu
- [2] Sequential Treatment of Advanced-stage Lung Adenocarcinoma Harboring Wild-type EGFR Gene: Second-line Pemetrexed Followed by Third-line Erlotinib versus the Reverse SequenceANTICANCER RESEARCH, 2013, 33 (08) : 3397 - 3402Fiala, OndrejPesek, MilosFinek, JindrichBenesova, LucieBortlicek, ZbynekMinarik, Marek
- [3] Apatinib as post second-line therapy in EGFR wild-type and ALK-negative advanced lung adenocarcinomaONCOTARGETS AND THERAPY, 2017, 10 : 447 - 452Fang, Shen-CunZhang, Hai-TaoZhang, Ying-MingXie, Wei-Ping
- [4] FINAL RESULTS OF CTONG 0806: A PHASE II TRIAL COMPARING PEMETREXED WITH GEFITINIB AS SECOND-LINE TREATMENT OF ADVANCED NON-SQUAMOUS NSCLC PATIENTS WITH WILD-TYPE EGFRJOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S194 - S195Zhou, QingCheng, YingZhao, Ming-FangYang, Jin-JiYan, Hong-HongZhang, LiSong, YongChen, Jian-HuaFeng, Wei-NengXu, Chong-RuiWu, Yi-Long
- [5] Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trialANNALS OF ONCOLOGY, 2014, 25 (12) : 2385 - 2391Zhou, Q.Cheng, Y.Yang, J. -J.Zhao, M. -F.Zhang, L.Zhang, X. -C.Chen, Z. -H.Yan, H. -H.Song, Y.Chen, J. -H.Feng, W. -N.Xu, C. -R.Wang, Z.Chen, H. -J.Zhong, W. -Z.Liu, Y. -P.Wu, Y. -L.
- [6] Phase II Trial of Erlotinib Monotherapy for Pretreated Elderly Patients with Advanced EGFR Wild-Type Non-Small-Cell Lung CancerJOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S547 - S547Minemura, HiroyukiYokouchi, HiroshiAzuma, KeisukeHirai, KenichiroSekine, SatokoOshima, KengoKanazawa, KenyaTanino, YoshinoriInokoshi, YayoiIshii, TaekoKatsuura, YutakaOishi, AkioIshida, TakashiMunakata, Mitsuru
- [7] A phase II trial of erlotinib monotherapy for pretreated elderly patients with advanced EGFR wild-type non-small cell lung cancer CancerBMC Research Notes, 8 (1)Minemura H.Yokouchi H.Azuma K.Hirai K.-I.Sekine S.Oshima K.Kanazawa K.Tanino Y.Inokoshi Y.Ishii T.Katsuura Y.Oishi A.Ishida T.Munakata M.
- [8] ERLOTINIB IN METASTATIC, EGFR WILD-TYPE, NON-SMALL CELL LUNG CANCER (NSCLC) AS SECOND OR FURTHER LINE OF THERAPYJOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1017 - S1017Hernandez, AlbaCalera, LourdesAlvarez, MariaHernando, JorgeTorres, IrenePajares, IsabelMadani, JuliaCebollero, AnaAnton-Torres, AntonioArtal, Angel
- [9] A Phase II Study of Carboplatin/Pemetrexed/Bevacizumab Followed by Bevacizumab/Erlotinib Maintenance for NonSq-NSCLC with Wild-Type EGFRJOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S546 - S546Yokouchi, HiroshiTakashina, TaichiAsahina, HajimeYamada, NoriyukiHarada, MasaoNakano, KosukeKanazawa, KenyaTakamura, KeiOgi, TakahiroHarada, ToshiyukiHonjo, OsamuMorikawa, NaotoKinoshita, IchiroHonda, RyoichiAmano, TorajiDosaka-Akita, HirotoshiIsobe, HiroshiNishimura, Masaharu
- [10] Clinical and biological significance of erlotinib therapy after pemetrexed in non-small cell lung cancer with wild-type EGFRNEOPLASMA, 2015, 62 (06) : 996 - 1004Koyama, N.Suzuki, M.